Figure 1
From: The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial
Kaplan–Meier estimates of (a) progression-free and (b) overall survival in relapsed ALL patients who received no asparaginase (n=16) and a 3:1 risk-stratified matched cohort of those who received PEG-Asparaginase (ASNase) (n=48).
